Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

478
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
478
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

539
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
539
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

511
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
511
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

591
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
591
  1. ホーム
  3. 心不全のフェノタイプ特有の治療法:多臓器のロードマップ
  1. ホーム
  3. 心不全のフェノタイプ特有の治療法:多臓器のロードマップ

関連する実験動画

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K

心不全のフェノタイプ特有の治療法:多臓器のロードマップ

Sanjiv J Shah1, Dalane W Kitzman1, Barry A Borlaug1

  • 1From Division of Cardiology, Department of Medicine, and the Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); Sections on Cardiovascular Medicine and Geriatrics, Wake Forest School of Medicine, Winston-Salem, NC (D.W.K.); Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN, (B.A.B.); Department of Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands (L.v.H., W.J.P.); Department of Cardiology, Onze Lieve Vrouw Gasthuis, Amsterdam, The Netherlands (L.v.H.); Department of Medicine, Medical University of South Carolina (MUSC) and the RHJ Department of Veterans Affairs Medical Center, Charleston (M.R.Z.); and Division of Cardiology, Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD (D.A.K.).

Circulation
|July 1, 2016

PubMed で要約を見る

まとめ
この要約は機械生成です。

保存されたエジェクション分数 (HFpEF) による心不全の治療には,併発症やさまざまな表型に対処する必要があります. パーソナライズされた戦略は,HFpEFに特有のシグナル伝達経路をターゲットにすることで,結果を改善します.

キーワード:
ディアストール心不全心不全,腹筋フェノタイプ治療薬左心室の機能

さらに関連する動画

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

関連する実験動画

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

科学分野:

  • 心臓病科
  • 内科 医学
  • 翻訳研究

背景:

  • 心臓機能不全と保存されたエジェクション分数 (HFpEF) は,心臓機能不全症例の50%を占める,増大する臨床的課題です.
  • HFpEFは,エジェクション分数が減少したHFとは異なり,従来の神経ユーモラル阻害療法に対して抵抗性を示しています.
  • 異なった全身的および心筋のシグナル伝達経路は,現象的多様性とともに,HFpEFの複雑さに寄与する.

研究 の 目的:

  • HFpEFの特殊なシグナル伝達機構と現象的変化を考慮した新しい治療戦略を提案する.
  • HFpEFにおける心臓の改造と機能不全を誘発する心臓外併発症の役割を明らかにする.
  • 特定されたシグナリングカスケード内の潜在的な治療標的を特定する.

主な方法:

  • HFpEFの病理学に関する現在の文献のレビュー,全身炎症と内皮機能不全に焦点を当てた.
  • 併発性疾患 (代謝リスク,高血圧,腎不全) と心臓の改造を結びつける信号経路の分析
  • HFpEFにおける特定の分子および細胞プロセスのための標的介入の探索.

主要な成果:

  • 心臓外併発症は,全身の炎症と冠動脈微小血管内皮機能不全によってHFpEFを誘発する.
  • これらのメカニズムは,左心室の透析機能不全,インタースティシャル線維症,心筋細胞の硬化につながる.
  • カロリー制限,スタチン,PDE5阻害剤,運動,利尿剤,ニートリート,ネプリリン/PDE9阻害剤,スピロノラクトンを含む複数の治療標的が特定されました.

    • 結論:

    • パーソナライズされた治療アプローチは,HFpEFのフェノタイプの多様性のために管理に不可欠です.
    • HFpEF特有のシグナリングカスケードをターゲットにすることは,治療開発の有望な道を提供します.
    • HFpEFの表現と傾向を考慮したマトリックスアプローチは,パーソナライズされた治療の選択を導くことができます.